Table 1.

Statistically Significant Differences in Eight SNPs among Patients with IgAN versus Control Subjects

	No. [%] of Subjects with
Zygosity	SELE8	SELE13	SELL1	SELL4	SELL5	SELL6	SELL10	SELL11
IgAN:
Major homozygotes	187 [57.89%]	189 [57.27%]	185 [54.41%]	157 [45.38%]	166 [48.26%]	133 [46.18%]	156 [53.24%]	161 [57.50%]
Heterozygotes	109 [33.75%]	115 [34.85%]	114 [33.53%]	138 [39.88%]	131 [38.08%]	106 [36.81%]	101 [34.47%]	95 [33.93%]
Minor homozygotes	27 [8.36%]	26 [7.88%]	41 [12.06%]	51 [14.74%]	47 [13.66%]	49 [17.01%]	36 [12.29%]	24 [8.57%]
Total	323 [100.00%]	330 [100.00%]	340 [100.00%]	346 [100.00%]	344 [100.00%]	288 [100.00%]	293 [100.00%]	280 [100.00%]
Major allele	483 [74.77%]	493 [74.70%]	484 [71.18%]	452 [65.32%]	463 [67.30%]	372 [64.58%]	413 [70.48%]	417 [74.46%]
Minor allele	163 [25.23%]	167 [25.30%]	196 [28.82%]	240 [34.68%]	225 [32.70%]	204 [35.42%]	173 [29.52%]	143 [25.54%]
Total	646 [100.00%]	660 [100.00%]	680 [100.00%]	692 [100.00%]	688 [100.00%]	576 [100.00%]	586 [100.00%]	560 [100.00%]
Control
Major homozygotes	269 [66.92%]	274 [67.16%]	246 [61.65%]	218 [53.96%]	227 [56.05%]	218 [58.76%]	235 [62.67%]	262 [67.88%]
Heterozygotes	120 [29.85%]	121 [29.66%]	139 [33.53%]	159 [39.36%]	154 [38.02%]	132 [35.58%]	126 [33.60%]	112 [29.02%]
Minor homozygotes	13 [3.23%]	13 [3.19%]	14 [3.51%]	27 [6.68%]	24 [5.93%]	21 [5.66%]	14 [3.73%]	12 [3.11%]
Total	402 [100.00%]	408 [100.00%]	399 [100.00%]	404 [100.00%]	405 [100.00%]	371 [100.00%]	375 [100.00%]	386 [100.00%]
Major allele	658 [81.84%]	669 [81.99%]	631 [79.07%]	595 [73.64%]	608 [75.06%]	568 [76.55%]	596 [79.47%]	636 [82.38%]
Minor allele	146 [18.16%]	147 [18.01%]	167 [20.93%]	213 [26.36%]	202 [24.94%]	174 [23.45%]	154 [20.53%]	136 [17.62%]
Total	804 [100.00%]	816 [100.00%]	798 [100.00%]	808 [100.00%]	810 [100.00%]	742 [100.00%]	750 [100.00%]	772 [100.00%]